Peptide Works
Research-Grade Peptides
A research peptide supplier built around three things: material that is what the label says, documentation that stands up to scrutiny, and delivery that arrives intact. This page explains how that work is done — and what we will not claim.
Peptide Works is a supplier of high-purity research peptides. We serve laboratories, universities, independent researchers and institutional purchasing teams who need material they can rely on, documentation they can file, and delivery that arrives when it is supposed to. Further information about the company’s background, quality standards and operating approach is available on Peptide Works about us.
That description is deliberately plain, because the work itself is plain. A researcher orders a compound. It needs to be what the label says. It needs to arrive intact. The paperwork needs to match the vial. When those three things happen consistently, the research moves forward and nobody thinks much about the supplier. When one fails, weeks of work can go with it — and often the researcher does not find out until the results have been written up.
Everything Peptide Works does is organised around getting those three things right, batch after batch. There is no clever fourth thing. There is only the unglamorous business of doing the same handful of steps correctly every time, including on the weeks when the schedule is tight and it would be easier not to.
This page explains how we approach that work, what we supply, how our material is tested and shipped, and just as importantly what we will not claim. That last part tends to get skipped on pages like this one, and the claims a company declines to make say at least as much as the ones it makes loudly.
Every product referenced on this website is supplied strictly for laboratory research and development use. That is not a footnote buried at the bottom of the page. It is the frame around everything else on it.
Peptide Works exists because of a problem that anyone who has purchased research peptides will recognise immediately, and probably has a specific memory attached to.
The supply market grew quickly, and faster than the standards holding it together. A lot of new sellers appeared over a short period. Some were serious operations with real analytical relationships behind them. Others were resellers with a website, a stock photograph of a laboratory they had never visited, and a purity figure copied from an upstream supplier they had never audited, never spoken to, and in some cases could not have named if asked.
From the outside, the two were almost indistinguishable. Same claims, similar pricing, the same confident vocabulary about quality and rigour. Both had a page much like this one, asserting a commitment to excellence in more or less identical language. A researcher comparing two suppliers on their websites was, in practice, comparing two pieces of copywriting.
The difference only surfaced later, and it surfaced expensively. In a batch that behaved differently from the last batch of the supposedly identical compound. In a Certificate of Analysis that could not be traced to an actual test on actual material no batch number, no laboratory named, no method disclosed, no date. In an order that sat in a customs facility for six weeks while the supplier's support address bounced. In a study that produced a clean, plausible, entirely wrong result, and nobody realised why until much later, if at all.
That last one is the failure that motivated us most, because it is the one that does the most damage while making the least noise. A shipment that never arrives is at least an obvious problem. A compromised compound that arrives on time, looks correct, and quietly corrupts a dataset can propagate for months before anyone catches it and by then, it has been built on.
We started Peptide Works to be the other kind of supplier. Not louder, not cheaper, not flashier, not the one with the most aggressive discounting or the most breathless product descriptions. Just consistent.
The founding principle was unglamorous, and we have never dressed it up: treat the documentation as part of the product. A peptide without verifiable analysis is not really a research material. It is a powder with a name on it and an assertion attached. The assertion might be true. It might even usually be true. But a researcher cannot build a study on an assertion, and should not be asked to.
So the testing relationships, the batch records, the storage protocols and the packaging standards were built into the operation from the beginning, rather than bolted on once the business was running. The alternative — build the storefront first, work out quality control later — is common enough here to have become the default, and it is very difficult to reverse once a company has grown into it. Quality systems are cheap to design in and expensive to retrofit.
We also made an early decision that has cost us the occasional sale and that we would make again: be honest about limits.
No supplier controls every customs office on earth. No batch of any peptide, produced by any method, is 100.0% pure — the chemistry does not permit it, and a company claiming otherwise is either careless with language or hoping the reader does not know enough to notice. No shipping route is immune to delay. Overstating any of this is easy, it converts slightly better in the short term, and it is precisely how a supplier spends down its credibility without noticing.
We would rather tell a researcher upfront that shipments to their region historically run long, or that a structurally complex peptide carries a slightly lower purity threshold than a simple sequence, than have them discover it after committing a study, a budget and a timeline to it. A researcher who was told the truth and planned around it is an inconvenienced customer. One who was told a comfortable story and found out later is a former customer, and rightly so.
That is more or less the whole story. It is not dramatic. We set out to be the supplier that does not create problems a surprisingly difficult standard to hold, and a surprisingly rare one to meet.
To support scientific work by supplying research peptides of verified purity, backed by documentation that stands up to scrutiny, and delivered reliably to researchers wherever they are.
Three commitments sit underneath that sentence, each of them an operational obligation rather than a sentiment.
Every claim Peptide Works makes about a compound traces back to an analytical result on a specific batch, performed by a laboratory with no commercial interest in the outcome. The purity figure attached to a product is not a category average, not an aspiration, and not a number inherited from an upstream supplier's paperwork and passed along unverified. It is a measurement. If we cannot point to the measurement, we do not make the claim.
The transaction is not finished when the payment clears, nor when the tracking number is generated. It is finished when the material is in the researcher's hands, intact, with its documentation, and they are satisfied with it. Everything between those points is ours to manage, including the parts that are inconvenient to manage.
Good research happens in a great many places, including places that are administratively awkward to ship to and that some suppliers quietly decline to serve because the paperwork is tedious. Peptide Works works to reach them anyway, with realistic expectations set in advance.
None of the three is complicated to understand. All three are demanding to sustain, because each costs something every time it is honoured. That cost is the point. A commitment that is free to keep is not a commitment; it is a slogan.
We want Peptide Works to become the supplier a researcher reorders from without thinking about it. Not out of inertia, and not because switching is a hassle, but because the material and the paperwork have been correct enough times in a row that checking has quietly stopped feeling necessary.
That is a strange thing to aim for, because success looks like absence. If we are doing this properly, the researcher does not think about us at all — not about whether the vial contains what it should, not about whether the certificate will hold up if purchasing asks a question, not about whether the shipment will clear customs. The supplier becomes invisible infrastructure, which is exactly what a supplier should be.
It is also a slow thing to build, and there is no shortcut to it. A supplier earns that position one clean batch at a time, over a period measured in years, and can undo a substantial portion of it with a single careless one. Trust here compounds slowly and decays quickly. That is an unfair arrangement, but an accurate one, and we are comfortable with the arithmetic. It is the only version of this business that lasts.
The Peptide Works catalogue covers a broad range of research peptides, supplied in several formats.
Format matters more than people outside the field tend to assume. It is not a packaging preference. It determines how a compound is stored, how it is handled at the bench, how it degrades over time, how much preparation sits between receiving the vial and running the experiment — and how many opportunities exist for variance to creep into the workflow. Every preparation step is a step where something can go slightly differently than it did last time.
The standard format, and for most research applications the correct one. Freeze-dried peptide in a sealed vial is stable, storable, and gives the researcher full control over reconstitution — solvent, concentration, volume, timing. It travels best, because removing water removes the medium through which most degradation pathways operate. It is also the format most laboratory protocols are written around, which means it slots into an existing workflow rather than requiring one to be redesigned. For long-term storage, and for any application where the researcher sets the working concentration themselves, it is almost always the right choice.
Pre-combined formulations supplied in a single vial. For research designs calling for a fixed combination of compounds, a blend removes a preparation step, and removes a source of variance with it. Reconstituting two or three compounds separately and combining them by hand means several operations, each carrying a small measurement uncertainty, and those uncertainties accumulate. A blend prepared to a specified ratio under controlled conditions eliminates that accumulation.
We are explicit about the composition and ratio of every blend we supply. That should be unremarkable, and yet blends with vague contents are common here. A blend whose exact composition is not stated is not usable research material — the researcher cannot report what they used, cannot reproduce it, and cannot compare it to anything.
Certain compounds are supplied in capsule form, for research applications where a solid, pre-measured, uniform unit suits the experimental design. The advantage is consistency of unit: where a study calls for a fixed quantity repeatedly, a capsule removes the per-instance measurement step and the variance that comes with it.
A prepared solution format, supplied for research contexts where that specific presentation is itself the subject of study. Delivery format is a legitimate research variable in its own right, and supplying a prepared spray allows it to be examined directly rather than approximated.
Pre-reconstituted, pre-loaded, and ready to store.
This format removes the reconstitution step entirely. Some research settings prefer that for consistency across an extended working period: every unit drawn during the study came from the same reconstitution event under the same conditions, rather than from a series of separate preparations, each with its own small deviation.
Among the catalogue entries, researchers can review Peptide Works Bronchogen Peptide when comparing available research compounds, formats and product-specific information.
Across all of these formats, the catalogue is deliberately wide, and that width is a considered decision rather than an accident of growth.
Research does not confine itself to a handful of well-known compounds. A supplier whose range stops at the popular twenty items is one a researcher has to abandon halfway through a project — at exactly the moment the work moves somewhere interesting. Sourcing the second half of a study elsewhere, with different synthesis, different testing standards and different documentation conventions, introduces an uncontrolled variable straight into the middle of it. So we carry breadth, including compounds that do not move in high volume, because the researcher working on the unfashionable compound has the same need for verified material as anyone else.
What we will not do, anywhere on this website or in any communication with a customer, is describe what these compounds do in a living system, or suggest applications outside a laboratory setting. Our role begins with sourcing and synthesis quality and ends with supplying verified material and the analysis that accompanies it. What is studied, why, and how belongs entirely to the researcher and to the framework they operate within. It is not our place to guide it, and we are not qualified to.
This is the section that matters most, so it is the longest one on this page. If you read nothing else here, read this.
A purity figure is usually treated as a badge — a number printed on a product page to signal seriousness. In practice it is nothing of the sort. It is a variable inside the researcher's experiment, and it operates there whether the researcher accounts for it or not.
Suppose a compound is 92% pure rather than the 99% stated on the label. The missing 8% is not empty space and it is not inert filler. It is something, and what it is depends on how the peptide was made, and how carefully.
In solid-phase synthesis, each amino acid is added in sequence, and each coupling step has an efficiency below 100%. The chains where a coupling failed do not vanish — they carry on through the remaining cycles as deletion sequences, missing one residue, otherwise near-identical to the target. Chains where synthesis terminated early become truncated sequences. Beyond those, the crude product can carry residual solvents, scavengers and reagents from the cleavage step, counter-ions, moisture, and aggregated or misfolded material that never adopted the correct conformation.
Some of these contaminants are inert and simply dilute the material. Some are not. Deletion and truncation sequences are the particular problem, and the reason is precisely their similarity to the target: close enough in structure to interfere with the same systems, different enough to behave in ways the target's own behaviour does not predict. They are, in effect, a second uncharacterised compound present at unknown concentration.
The consequence is a study measuring something other than what it believes it is measuring. And here is what makes that dangerous rather than merely wasteful: the error is invisible. No anomaly. No obvious failure. No error bar that blows out. Nothing signalling that anything has gone wrong. There is simply a result — clean, plausible, internally consistent and wrong. It gets recorded, analysed, written up, and sometimes built upon.
The second problem is consistency, and it gets the least attention relative to the damage it does. A supplier whose batches range between 88% and 99% has not merely delivered variable quality; it has introduced an uncontrolled variable that varies across time. A researcher comparing this month's results against last quarter's, using the same compound from the same supplier under the same protocol, is unknowingly comparing two different materials. Every conclusion drawn from that comparison is contaminated. Reproducibility — the property the scientific method rests on — has quietly stopped working, and no diagnostic will reveal it, because from the researcher's side nothing changed.
This is why Peptide Works treats purity as a supply obligation rather than a selling point. It is not a feature bolted onto the product. It is the product. The vial is packaging.
Peptide Works works to a minimum purity threshold of 99% across the catalogue.
For structurally complex peptides — longer sequences, peptides incorporating difficult residues, those requiring cyclisation, disulfide bridging or specific modifications — the threshold is 98%.
We state this openly rather than folding those compounds under a blanket 99% claim and hoping nobody looks closely. Synthesis chemistry does not accommodate marketing consistency. Longer sequences require more coupling steps, and every additional step is another opportunity for a small failure that compounds through the remaining chain. Aggregation-prone sequences resist efficient coupling. Modified and cyclised peptides require further chemistry after assembly, each stage introducing its own potential for by-products.
A supplier claiming an identical purity ceiling across every compound in a broad catalogue is making a claim that anyone with a working knowledge of peptide chemistry can see through immediately. We would rather be accurate and trusted than uniform and doubted.
Every batch is tested. Not a representative batch. Not the first of a production run, with the rest assumed to match. Not periodic spot-checks on a rolling schedule. Every batch. Testing is carried out by independent third-party laboratories with no commercial stake in the result.
This is not a formality, and it is not interchangeable with in-house quality control, however good that in-house capability may be. A supplier that tests its own material and issues its own certificate is grading its own homework. Nothing structurally prevents it from grading generously, and there is a constant, quiet commercial pressure encouraging exactly that. A borderline batch, tested internally, with a customer waiting and a shipment due, is a situation in which honest people make optimistic judgements.
Independent verification introduces the one thing self-certification cannot: a party with no reason whatsoever to say the batch passed. That laboratory does not care about our dispatch schedule, our margin or our customer's deadline. It reports what it measures, and that indifference is the entire value of the arrangement.
Each batch is analysed for identity — confirming the compound present is the sequence it is supposed to be, at the correct molecular mass, rather than a similar, mislabelled or degraded one — and for purity, quantifying the target compound against every other species present.
Every batch carries a Certificate of Analysis, and it is available to the researcher who receives material from that batch.
A COA is only useful if it is traceable to a specific lot. Generic certificates are widespread, and they are worse than useless: they provide the appearance of verification without the substance, which means the researcher who accepts one has been handed a reason to stop asking questions.
An undated certificate, with no batch number, no laboratory identified and no method described, tells the researcher exactly this — that a test was performed on something, somewhere, at some point, by someone. That is not evidence. It is the shape of evidence with the content removed.
A Peptide Works Certificate of Analysis identifies the batch, names the testing laboratory, states the analytical methods used and reports the results obtained. If a purchasing officer wants to verify the material in front of them, they can. If a principal investigator wants to satisfy themselves before committing a study to it, they can. If an institutional review process asks for supporting documentation, the document holds up when it is examined — the only test of a certificate that actually matters. No researcher should be placed in the position of defending their supplier's paperwork.
Purity at the point of synthesis means nothing whatsoever if the material degrades before it reaches the bench. This is the half of the quality equation that suppliers most often ignore, because it happens after the sale and outside the laboratory, where nobody is watching.
Peptides are sensitive materials — to heat, which accelerates hydrolysis and oxidation; to moisture, which enables both; to light, where photosensitive residues are present; to oxidation at exposed residues; and to repeated freeze-thaw cycling, which promotes aggregation. A compound that leaves a facility at 99% and arrives having passed through a heated warehouse, an uninsulated transit leg and a week on a depot shelf is, for practical purposes, compromised — and its Certificate of Analysis now describes a material that no longer exists.
Lyophilisation, correct storage, appropriate packaging and transit arrangements suited to the compound are therefore not logistics details to be optimised for cost. They are the second half of the purity commitment, and a supplier that takes the first half seriously while treating the second as a shipping expense has not understood the problem it is solving. We treat them as one continuous obligation, running from synthesis to the researcher's freezer.
Orders are stored under conditions appropriate to the compound, and prepared for transit on the assumption that transit will be imperfect — because, over enough shipments, it always is.
Packaging is protective rather than merely presentable. Vials are secured against impact, vibration and the crushing loads that packages meet in automated sorting facilities. Where a compound requires temperature control, packaging is specified to hold that condition for longer than the expected transit duration rather than merely for it — because the expected duration is a forecast, and forecasts are wrong.
Where a compound is light-sensitive, the packaging accounts for it. Where it is moisture-sensitive, the seal and desiccation are specified to match. The compound determines the packaging, not the warehouse's convenience.
Shipments are discreet. Exterior packaging carries no indication of contents — not secrecy, simply standard practice for any material of value moving through a public logistics network.
Documentation travels with the order or is made available alongside it. Material and paperwork should not be separated. A vial in a freezer with no traceable certificate is, six months later, simply an unidentifiable vial in a freezer.
Support at Peptide Works does not end at dispatch confirmation.
That is a low bar, and we are aware of how low it is. It is also one that a surprising number of suppliers fail to clear. Once payment has settled and a tracking number has been issued, the responsiveness evaporates. Emails go unanswered for days and then are answered with nothing. A tracking query receives a copy-pasted link to the courier's website, as if the customer had not already tried that. A request for a Certificate of Analysis disappears into a queue and never emerges. A shipment stuck in customs becomes the courier's problem, or the authority's problem, or the customer's problem — anyone's but theirs.
Our position is straightforward. The order is complete when the researcher has the material, intact, with its documentation, and is satisfied with it. Not before. Everything up to that point is ours to see through — including the tedious parts, and including the parts that are not, strictly speaking, our fault.
Just as importantly, they know the range they are supporting. A researcher with a specific question about a compound's format, batch documentation or storage requirement should not have to explain the basics of the field to the person answering. Generic outsourced support, working from a script, cannot do this; it can only match a question against a list of approved responses, and anything outside the list produces a non-answer or a silence.
There is one category of request our team cannot help with, and we would rather state it plainly here than deflect it awkwardly in an email six months from now.
We do not provide dosing information. We do not provide administration protocols. We do not provide any guidance relating to use in humans or in animals — not privately on request, not off the record, not as a personal opinion.
This is not unhelpfulness for its own sake, and it is not a legal formality recited while the tone implies something else. Our products are research materials. Providing that guidance would misrepresent both what we supply and what we are qualified to advise on. Our expertise is in synthesis quality, analytical verification, handling and logistics, and expertise in those areas confers no authority over pharmacology or outcomes. If a question falls into that category, the answer will be no — every time, however it is phrased, whoever is asking.
Peptide Works ships to most countries worldwide. Shipments are tracked from dispatch, and shipping protection is available to cover orders in transit. Where a delivery goes wrong — and across a sufficient volume of international shipments, some proportion always will — the support team works the problem rather than pointing at the courier and considering the matter closed.
We are also going to be straightforward about the parts of this process we do not control, because a supplier who is vague about them is being vague deliberately.
Customs procedures differ substantially by country, and they change without notice or publicity. Some regions clear consistently and quickly. Others are unpredictable in ways no amount of correct paperwork will fully resolve. Transit times vary by destination, by season and by carrier capacity. No supplier can guarantee a delivery date on an international shipment while remaining truthful, and any supplier that does is either careless with words or hoping you will not remember them.
A supplier who promises that a customs office will behave has decided a comfortable answer today is worth more than credibility next quarter. We think that is a poor trade, and we have declined to make it.
Every batch is independently tested by a laboratory with no stake in the result, and carries a Certificate of Analysis traceable to that lot, naming the laboratory and disclosing the method. The 99% threshold — 98% for structurally complex peptides — is a standard we work to and verify against, not a number chosen because it looked reassuring in a product listing. If we cannot evidence a claim, we do not make it.
Purchasing departments ask questions. Principal investigators ask questions. Institutional review processes ask them at inconvenient moments. Our documentation is written on the assumption that it will be examined by someone competent looking for a reason to reject it: batch-specific, laboratory-attributed, method-disclosed.
A wide range of compounds is available as lyophilised vials, blends, stacks, capsules, nasal sprays and pre-mixed pens. The catalogue also contains product-specific research material pages, including Peptide Works Thymosin Alpha-1. Protocols vary enormously, and a researcher should not be redesigning a workflow around a supplier's limited format options — nor changing suppliers mid-project because the catalogue ran out of relevance at exactly the point the work got interesting.
The most underrated quality in a supplier, and the hardest to demonstrate on a website. Consistency is what makes a longitudinal study valid and what allows a result from March to be honestly compared with one from November. It is invisible when it works and catastrophic when it does not — which is precisely why so few suppliers invest properly in it, and precisely why we do.
Our team understands the catalogue it is supporting and stays involved after the parcel has left. Researchers get answers rather than deflections, from people who can follow a technical question without having it explained first. They also get a clear, consistent no on the questions we will not answer, which is its own form of respect.
We ship widely, we track shipments, and we offer shipping protection. And we tell researchers the truth about what transit to their region typically involves — including when a more optimistic answer would close the sale.
Peptide Works supplies research materials. That is the complete scope of what we do, and we are careful — deliberately, sometimes inconveniently careful — about the boundaries of it.
Everything we supply is labelled for laboratory research and development use only. We do not make health claims, therapeutic claims or performance claims. We do not publish protocols, dosing guidance or administration instructions; we do not host content that functions as those things while avoiding the words; and we do not provide them privately when asked directly.
This is a genuine position rather than a legal shield with a wink attached, and the distinction matters, because the wink is common enough here to have become an unspoken convention. Some suppliers observe the letter of the research-use framing on their product pages while their blog, their support channel and their marketing copy carry a very different message. We think that is dishonest, and everybody involved knows it is.
Our reasoning is not primarily about liability. It is about what we actually know.
Peptides are the subject of substantial and legitimate scientific investigation. Their properties and mechanisms across various contexts remain under active study, and much of what will eventually be understood is not understood yet. That is exactly why a supplier has no business making pronouncements about them. The uncertainty is the point of the research; a company selling into that research while announcing conclusions about it has misunderstood its own role.
Our expertise is real and it is narrow: synthesis quality, analytical verification, handling, stability and logistics. It is not pharmacology and it is not clinical outcomes, and we do not intend to pretend otherwise for the sake of a more exciting website.
The commitment running alongside that restraint is transparency about the things we do know. Purity thresholds stated accurately, including — especially including — where they are lower than we would prefer. Analytical methods disclosed rather than gestured at. Batch documentation made available rather than promised. Shipping realities described honestly. Limits admitted plainly rather than glossed over with confident language.
A researcher deciding whether to trust a supplier deserves to know what that supplier actually knows — and, just as importantly, precisely where its knowledge stops.
Strip away the presentation and a peptide supplier is doing a simple job. Produce or source the compound. Verify independently that it is what it claims to be. Document the verification so it can be traced and checked. Store it under the right conditions. Ship it so it arrives intact. Answer the phone afterwards.
Six steps. None requires genius. None is a secret. Any competent operation could do all six, and many claim to.
Almost every failure in this market is a failure of one of those steps — and, tellingly, almost none is a failure of intent. Nobody sets out to ship a bad batch. They are failures of discipline, and they happen at the margins, on ordinary days, for ordinary reasons. A batch shipped without testing because the schedule was tight and the last several were fine. A certificate reissued from a previous lot because the new analysis had not come back and a customer was waiting. Packaging downgraded to save a little per parcel across a great many parcels. A borderline purity result accepted because rejecting it meant a difficult conversation.
Each of those decisions is small, defensible in the moment, and invisible to the customer. Collectively, they are the difference between a supplier you can build a research programme on and one you cannot.
Peptide Works is built to be disciplined about the boring parts. That is not an exciting thing to write on a website, and it reads as almost apologetically modest next to the language most suppliers reach for. But discipline about the boring parts is exactly what a researcher is buying when they buy from a supplier they trust, and it is what we have chosen to be good at — because it is difficult, because most companies are not, and because it is the only thing on this page that actually protects the person doing the research.
If our material arrives when we said it would, tests as we said it would, stores as it should, and never once causes a researcher to stop and wonder whether the compound was the problem, then the job is done. We do not need it to be more interesting than that.
All products supplied by Peptide Works are intended strictly for laboratory research and development purposes only.
These products are not for human or animal consumption or ingestion of any kind.
The information, statements and products featured on this website are provided for research and educational purposes only. Nothing on this page, and nothing elsewhere on this website, is intended to diagnose, treat, cure or prevent any condition, and no statement here should be interpreted as guidance for use outside a controlled laboratory setting.